Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance

Citius Pharmaceuticals IncTrade
Consumer Discretionary Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M), while Consumer Discretionary Select Sector SPDR Fund trades at $118.1. The key difference: Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRXLY
Market Cap
$20.01M
Sector
Health
52-Week High
$1.82$124.52
52-Week Low
$0.48$105.64
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Consumer Discretionary Select Sector SPDR Fund

XLY trades at $118.93, down 0.62% today, with a bullish technical signal from moving averages and neutral oscillators. Analyst consensus is unanimously positive with a 100% buy rating. The ETF shows strong technical momentum, though RSI levels indicate potential overbought conditions near-term.

The outlook remains favorable given bullish analyst sentiment and technical trends, but risks include consumer spending sensitivity to inflation and concentrated holdings. Upside potential hinges on sustained discretionary spending, while economic slowdowns pose a threat to performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Consumer Discretionary Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.

Read more on XLY